Share Price and Basic Stock Data
Last Updated: January 24, 2026, 4:48 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Suven Life Sciences Ltd operates within the pharmaceuticals sector, focusing on the development and commercialization of innovative drug substances. The company’s share price stood at ₹135, with a market capitalization of ₹3,076 Cr. Revenue trends have shown significant volatility, with total sales reported at ₹14 Cr for FY 2023, a decline from ₹12 Cr in FY 2022. The trailing twelve months (TTM) revenue further fell to ₹6 Cr, indicating a severe downturn in operational performance. Quarterly sales figures reflected this downward trajectory, peaking at ₹4 Cr in both September 2022 and June 2023, but subsequently declining to just ₹2 Cr by December 2023. This suggests challenges in maintaining consistent revenue streams, which are critical for sustaining operations and funding future growth initiatives.
Profitability and Efficiency Metrics
Profitability metrics for Suven Life Sciences Ltd paint a concerning picture. The company reported a net profit of -₹212 Cr for the TTM, marking a continued trend of losses that have persisted over several years. Operating profit margins (OPM) were notably negative, declining to -8,671% in September 2025, reflecting the company’s inability to cover its operating costs with its revenues. Efficiency ratios such as Return on Equity (ROE) and Return on Capital Employed (ROCE) were recorded at 87.2% and 87.0%, respectively, indicating high returns relative to shareholder equity and capital employed. However, these figures contrast sharply with the company’s negative profitability, suggesting that while capital is being utilized efficiently, it is not translating into positive earnings. The cash conversion cycle of 73 days indicates a relatively extended period in converting sales into cash, compounding the existing profitability challenges.
Balance Sheet Strength and Financial Ratios
Suven Life Sciences Ltd’s balance sheet reflects a precarious financial position, characterized by zero borrowings, which is advantageous in terms of debt management. The company reported reserves of ₹259 Cr, a notable decrease from ₹354 Cr in the previous year, indicating a depletion of retained earnings amid ongoing operational losses. The price-to-book value ratio stood at 22.48x, significantly above typical sector ranges, suggesting that the market may be overvaluing the company relative to its net assets. Financial ratios such as the interest coverage ratio (ICR) were alarmingly low at -3323.53x, indicating extreme difficulty in meeting any potential interest obligations, despite the absence of debt. This situation raises concerns about liquidity and the overall financial health of the company, as the high P/BV ratio and negative profitability metrics could deter potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Suven Life Sciences Ltd indicates a strong promoter presence, with promoters holding 67.36% of the company’s equity. This is a slight decline from previous quarters but still reflects a significant level of commitment from the founders. Foreign Institutional Investors (FIIs) have increased their stake marginally to 1.17%, while Domestic Institutional Investors (DIIs) have raised their holdings to 3.39%. The public shareholding stood at 28.07%, suggesting a healthy distribution among retail investors. However, the declining number of shareholders from 80,838 in December 2022 to 64,921 in September 2025 raises concerns regarding investor confidence. The high promoter ownership coupled with low institutional participation may limit the company’s ability to attract new investments, which is critical for recovery and growth.
Outlook, Risks, and Final Insight
The outlook for Suven Life Sciences Ltd presents a mix of opportunities and significant risks. The company’s strong ROE and ROCE ratios indicate potential for high returns once profitability is restored. However, the persistent operating losses and negative profit margins represent critical risks that could hinder recovery efforts. The absence of debt offers a buffer against financial distress but may also limit growth through leverage. If the company can stabilize its operations and reverse the declining revenue trend, it may regain investor confidence and improve its market position. Conversely, continued operational inefficiencies and lack of revenue generation could lead to further erosion of shareholder value. The path forward will require strategic restructuring and a focus on enhancing revenue streams to mitigate the risks associated with its current financial standing.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 197/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,463 Cr. | 318 | 479/192 | 71.7 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 43.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,525.73 Cr | 1,087.19 | 47.43 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 3 | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 |
| Expenses | 26 | 55 | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 |
| Operating Profit | -22 | -52 | -32 | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 |
| OPM % | -494% | -1,719% | -1,208% | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% |
| Other Income | 0 | 2 | 6 | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Profit before tax | -23 | -51 | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -23 | -51 | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 |
| EPS in Rs | -1.06 | -2.34 | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 |
Last Updated: December 28, 2025, 11:04 pm
Below is a detailed analysis of the quarterly data for Suven Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Expenses, as of Sep 2025, the value is 81.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 53.00 Cr. (Jun 2025) to 81.00 Cr., marking an increase of 28.00 Cr..
- For Operating Profit, as of Sep 2025, the value is -80.00 Cr.. The value appears to be declining and may need further review. It has decreased from -51.00 Cr. (Jun 2025) to -80.00 Cr., marking a decrease of 29.00 Cr..
- For OPM %, as of Sep 2025, the value is -8,671.00%. The value appears to be declining and may need further review. It has decreased from -2,714.00% (Jun 2025) to -8,671.00%, marking a decrease of 5,957.00%.
- For Other Income, as of Sep 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 4.00 Cr., marking an increase of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -77.00 Cr.. The value appears to be declining and may need further review. It has decreased from -52.00 Cr. (Jun 2025) to -77.00 Cr., marking a decrease of 25.00 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -77.00 Cr.. The value appears to be declining and may need further review. It has decreased from -52.00 Cr. (Jun 2025) to -77.00 Cr., marking a decrease of 25.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -3.40. The value appears to be declining and may need further review. It has decreased from -2.36 (Jun 2025) to -3.40, marking a decrease of 1.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 6 |
| Expenses | 105 | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 219 |
| Operating Profit | 13 | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -214 |
| OPM % | 11% | 31% | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,638% |
| Other Income | 3 | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 7 |
| Interest | 5 | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 |
| Profit before tax | 6 | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -212 |
| Tax % | -32% | 28% | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | |
| Net Profit | 8 | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -212 |
| EPS in Rs | 0.48 | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -9.56 |
| Dividend Payout % | 35% | 7% | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.94% | 20.83% | 42.53% | -119.35% | -291.67% | 23.40% | -69.44% | 3.28% | 11.02% | -53.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 54.78% | 21.70% | -161.88% | -172.31% | 315.07% | -92.85% | 72.72% | 7.74% | -64.35% |
Suven Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -35% |
| 5 Years: | -12% |
| 3 Years: | -17% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -24% |
| 3 Years: | -12% |
| TTM: | -58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 36% |
| 3 Years: | 43% |
| 1 Year: | 40% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -62% |
| 3 Years: | -55% |
| Last Year: | -87% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: January 7, 2026, 4:29 pm
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 23 |
| Reserves | 95 | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 259 |
| Borrowings | 55 | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | -0 | -0 |
| Other Liabilities | 38 | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 56 |
| Total Liabilities | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 337 |
| Fixed Assets | 110 | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 58 |
| CWIP | 4 | 107 | 7 | 10 | 25 | 0 | -0 | 5 | 4 | -0 | -0 | 0 | 1 |
| Investments | 2 | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 247 |
| Other Assets | 83 | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 32 |
| Total Assets | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 337 |
Below is a detailed analysis of the balance sheet data for Suven Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 259.00 Cr.. The value appears strong and on an upward trend. It has increased from 88.00 Cr. (Mar 2025) to 259.00 Cr., marking an increase of 171.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 56.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 31.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 337.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 135.00 Cr. (Mar 2025) to 337.00 Cr., marking an increase of 202.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 225.00 Cr..
- For Other Assets, as of Sep 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Mar 2025) to 32.00 Cr., marking a decrease of 21.00 Cr..
- For Total Assets, as of Sep 2025, the value is 337.00 Cr.. The value appears strong and on an upward trend. It has increased from 135.00 Cr. (Mar 2025) to 337.00 Cr., marking an increase of 202.00 Cr..
Notably, the Reserves (259.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -42.00 | 50.00 | 19.00 | 58.00 | 164.00 | -17.00 | -122.00 | -85.00 | -125.00 | -128.00 | -129.00 | -166.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Inventory Days | 200 | 165 | 183 | 222 | 329 | 0 | ||||||
| Days Payable | 157 | 89 | 78 | 91 | 134 | |||||||
| Cash Conversion Cycle | 154 | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Working Capital Days | 139 | 49 | 55 | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 |
| ROCE % | 8% | 13% | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Balanced Advantage Fund | 4,143,548 | 0.2 | 219.03 | 3,353,052 | 2026-01-25 13:37:44 | 23.58% |
| HDFC Flexi Cap Fund | 4,000,000 | 0.22 | 211.44 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 3,672,095 | 3.01 | 194.11 | 3,068,016 | 2026-01-25 13:50:47 | 19.69% |
| Invesco India Contra Fund | 3,598,511 | 0.92 | 190.22 | 3,323,946 | 2025-12-14 11:28:18 | 8.26% |
| DSP ELSS Tax Saver Fund | 3,285,254 | 0.99 | 173.66 | N/A | N/A | N/A |
| DSP Healthcare Fund | 2,967,600 | 5.04 | 156.87 | N/A | N/A | N/A |
| DSP Large & Mid Cap Fund | 2,762,648 | 0.83 | 146.03 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,540,619 | 0.51 | 134.3 | N/A | N/A | N/A |
| DSP Flexi Cap Fund | 2,453,891 | 1.05 | 129.71 | N/A | N/A | N/A |
| Canara Robeco Small Cap Fund | 2,261,293 | 0.91 | 119.53 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Diluted EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Cash EPS (Rs.) | -7.10 | -4.52 | -5.12 | -8.09 | -5.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Revenue From Operations / Share (Rs.) | 0.30 | 0.53 | 0.62 | 0.81 | 1.06 |
| PBDIT / Share (Rs.) | -7.10 | -4.90 | -5.39 | -8.05 | -5.68 |
| PBIT / Share (Rs.) | -7.37 | -5.20 | -5.69 | -8.35 | -6.02 |
| PBT / Share (Rs.) | -7.37 | -4.86 | -5.42 | -8.39 | -6.09 |
| Net Profit / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| NP After MI And SOA / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| PBDIT Margin (%) | -2326.94 | -914.01 | -867.37 | -988.42 | -536.50 |
| PBIT Margin (%) | -2414.41 | -969.62 | -915.70 | -1025.51 | -568.75 |
| PBT Margin (%) | -2415.11 | -907.20 | -873.52 | -1029.98 | -574.80 |
| Net Profit Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| NP After MI And SOA Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| Return on Networth / Equity (%) | -146.14 | -38.91 | -31.51 | -126.88 | -66.80 |
| Return on Capital Employeed (%) | -143.86 | -41.77 | -32.81 | -121.80 | -68.13 |
| Return On Assets (%) | -118.90 | -36.88 | -30.41 | -112.92 | -56.18 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 |
| Current Ratio (X) | 3.21 | 18.99 | 22.61 | 8.01 | 6.45 |
| Quick Ratio (X) | 3.20 | 18.94 | 22.61 | 8.01 | 6.45 |
| Inventory Turnover Ratio (X) | 14.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -3323.53 | -674.71 | -406.21 | -220.85 | -88.68 |
| Interest Coverage Ratio (Post Tax) (X) | -3448.46 | -709.43 | -428.84 | -229.14 | -87.49 |
| Enterprise Value (Cr.) | 2435.23 | 2010.22 | 872.72 | 1343.38 | 849.81 |
| EV / Net Operating Revenue (X) | 365.88 | 171.92 | 64.46 | 113.42 | 63.05 |
| EV / EBITDA (X) | -15.72 | -18.81 | -7.43 | -11.47 | -11.75 |
| MarketCap / Net Operating Revenue (X) | 371.55 | 185.94 | 78.07 | 113.85 | 66.48 |
| Price / BV (X) | 22.48 | 8.05 | 2.82 | 14.02 | 8.30 |
| Price / Net Operating Revenue (X) | 371.56 | 185.97 | 78.08 | 113.85 | 66.48 |
| EarningsYield | -0.06 | -0.04 | -0.11 | -0.09 | -0.08 |
After reviewing the key financial ratios for Suven Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Cash EPS (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 3. It has decreased from -4.52 (Mar 24) to -7.10, marking a decrease of 2.58.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.30. It has decreased from 0.53 (Mar 24) to 0.30, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 2. It has decreased from -4.90 (Mar 24) to -7.10, marking a decrease of 2.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -5.20 (Mar 24) to -7.37, marking a decrease of 2.17.
- For PBT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -4.86 (Mar 24) to -7.37, marking a decrease of 2.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For PBDIT Margin (%), as of Mar 25, the value is -2,326.94. This value is below the healthy minimum of 10. It has decreased from -914.01 (Mar 24) to -2,326.94, marking a decrease of 1,412.93.
- For PBIT Margin (%), as of Mar 25, the value is -2,414.41. This value is below the healthy minimum of 10. It has decreased from -969.62 (Mar 24) to -2,414.41, marking a decrease of 1,444.79.
- For PBT Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 10. It has decreased from -907.20 (Mar 24) to -2,415.11, marking a decrease of 1,507.91.
- For Net Profit Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 5. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 8. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For Return on Networth / Equity (%), as of Mar 25, the value is -146.14. This value is below the healthy minimum of 15. It has decreased from -38.91 (Mar 24) to -146.14, marking a decrease of 107.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is -143.86. This value is below the healthy minimum of 10. It has decreased from -41.77 (Mar 24) to -143.86, marking a decrease of 102.09.
- For Return On Assets (%), as of Mar 25, the value is -118.90. This value is below the healthy minimum of 5. It has decreased from -36.88 (Mar 24) to -118.90, marking a decrease of 82.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.03. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Current Ratio (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has decreased from 18.99 (Mar 24) to 3.21, marking a decrease of 15.78.
- For Quick Ratio (X), as of Mar 25, the value is 3.20. This value exceeds the healthy maximum of 2. It has decreased from 18.94 (Mar 24) to 3.20, marking a decrease of 15.74.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.07. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 14.07, marking an increase of 14.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -3,323.53. This value is below the healthy minimum of 3. It has decreased from -674.71 (Mar 24) to -3,323.53, marking a decrease of 2,648.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3,448.46. This value is below the healthy minimum of 3. It has decreased from -709.43 (Mar 24) to -3,448.46, marking a decrease of 2,739.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,435.23. It has increased from 2,010.22 (Mar 24) to 2,435.23, marking an increase of 425.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 365.88. This value exceeds the healthy maximum of 3. It has increased from 171.92 (Mar 24) to 365.88, marking an increase of 193.96.
- For EV / EBITDA (X), as of Mar 25, the value is -15.72. This value is below the healthy minimum of 5. It has increased from -18.81 (Mar 24) to -15.72, marking an increase of 3.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 371.55. This value exceeds the healthy maximum of 3. It has increased from 185.94 (Mar 24) to 371.55, marking an increase of 185.61.
- For Price / BV (X), as of Mar 25, the value is 22.48. This value exceeds the healthy maximum of 3. It has increased from 8.05 (Mar 24) to 22.48, marking an increase of 14.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 371.56. This value exceeds the healthy maximum of 3. It has increased from 185.97 (Mar 24) to 371.56, marking an increase of 185.59.
- For EarningsYield, as of Mar 25, the value is -0.06. This value is below the healthy minimum of 5. It has decreased from -0.04 (Mar 24) to -0.06, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Suven Life Sciences Ltd:
- Net Profit Margin: -2415.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -143.86% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -146.14% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3448.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.2
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 47.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2415.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vivek Sharma | Executive Chairman |
| Dr. V Prasada Raju | Managing Director |
| Mr. Pankaj Patwari | Non Executive Director |
| Ms. Shweta Jalan | Non Executive Director |
| Mr. Vinod Padikkal | Non Executive Director |
| Mr. Vinod Rao | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. U B Pravin Rao | Independent Director |
| Ms. Matangi Gowrishankar | Independent Director |
| Mr. Jai Shankar Krishnan | Independent Director |
FAQ
What is the intrinsic value of Suven Life Sciences Ltd?
Suven Life Sciences Ltd's intrinsic value (as of 25 January 2026) is ₹96.04 which is 28.33% lower the current market price of ₹134.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,050 Cr. market cap, FY2025-2026 high/low of ₹303/102, reserves of ₹259 Cr, and liabilities of ₹337 Cr.
What is the Market Cap of Suven Life Sciences Ltd?
The Market Cap of Suven Life Sciences Ltd is 3,050 Cr..
What is the current Stock Price of Suven Life Sciences Ltd as on 25 January 2026?
The current stock price of Suven Life Sciences Ltd as on 25 January 2026 is ₹134.
What is the High / Low of Suven Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Suven Life Sciences Ltd stocks is ₹303/102.
What is the Stock P/E of Suven Life Sciences Ltd?
The Stock P/E of Suven Life Sciences Ltd is .
What is the Book Value of Suven Life Sciences Ltd?
The Book Value of Suven Life Sciences Ltd is 12.4.
What is the Dividend Yield of Suven Life Sciences Ltd?
The Dividend Yield of Suven Life Sciences Ltd is 0.00 %.
What is the ROCE of Suven Life Sciences Ltd?
The ROCE of Suven Life Sciences Ltd is 87.0 %.
What is the ROE of Suven Life Sciences Ltd?
The ROE of Suven Life Sciences Ltd is 87.2 %.
What is the Face Value of Suven Life Sciences Ltd?
The Face Value of Suven Life Sciences Ltd is 1.00.